Drug Profile
IFN alpha CS(g) - Dekk-Tec
Alternative Names: IFN-y fusion proteins - Dekk Tec; IFN-α fusion proteins - Dekk Tec; Recombinant fusion IFN alpha CS(g) - Dekk TecLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Dekk-Tec; University of Texas M. D. Anderson Cancer Center
- Class Antivirals; Interferons; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Surface antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Hepatitis-C in USA
- 29 Jan 2020 Preclinical development is ongoing for Hepatitis-C in USA (Dekk Tec pipeline, January 2020)
- 28 Feb 2019 No recent reports of development identified for research development in Hepatitis-C in USA